U.S. markets open in 6 hours 4 minutes
  • S&P Futures

    4,412.75
    -2.25 (-0.05%)
     
  • Dow Futures

    34,977.00
    -21.00 (-0.06%)
     
  • Nasdaq Futures

    15,059.50
    +13.25 (+0.09%)
     
  • Russell 2000 Futures

    2,216.10
    -3.30 (-0.15%)
     
  • Crude Oil

    70.21
    -0.35 (-0.50%)
     
  • Gold

    1,816.80
    +2.70 (+0.15%)
     
  • Silver

    25.75
    +0.17 (+0.68%)
     
  • EUR/USD

    1.1879
    +0.0011 (+0.10%)
     
  • 10-Yr Bond

    1.1760
    0.0000 (0.00%)
     
  • Vix

    18.04
    -1.42 (-7.30%)
     
  • GBP/USD

    1.3945
    +0.0030 (+0.21%)
     
  • USD/JPY

    109.1330
    +0.0830 (+0.08%)
     
  • BTC-USD

    37,788.63
    -720.99 (-1.87%)
     
  • CMC Crypto 200

    924.03
    -19.41 (-2.06%)
     
  • FTSE 100

    7,138.71
    +32.99 (+0.46%)
     
  • Nikkei 225

    27,584.08
    -57.75 (-0.21%)
     

Vir Biotech Stock Jumps After FDA Emergency Use Approval COVID-19 Antibody Drug

·1 min read
  • The FDA has given an emergency use authorization (EUA) to COVID-19 antibody treatment developed by Vir Biotechnology Inc (NASDAQ: VIR) and GlaxoSmithKline Plc (NYSE: GSK) for treating mild-to-moderate COVID-19 in people aged 12 years and older.

  • The EUA comes after Vir’s antibody proved 85% effective at preventing hospitalization in high-risk, newly diagnosed COVID-19 patients.

  • The antibody, Sotrovimab, is not authorized for hospitalized patients due to COVID-19 or require oxygen therapy.

  • The antibody treatment will be available for COVID-19 patients in the coming weeks, GSK and Vir said, adding that they plan to submit a marketing application to the FDA in the second half of 2021.

  • Last week, the European Union’s CHMP backed the use of Sotrovimab for COVID-19 patients who were at risk of severe disease and did not need supplemental oxygen.

  • Price Action: VIR shares are up 9.27% at $50, while GSK shares are down 0.67% at $38.45 during the premarket session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.